References
- Scalo JF, Rascati KL. Trends and issues in oncology costs. Expert Rev Pharmacoecon Outcomes Res. 2014;14(1):35–44.
- Michel M, Toumi M. Access to orphan drugs in Europe: current and future issues. Exp Rev Pharmacoecon & Outcomes Res. 2012;12:23–29.
- World Health Organization. Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research Geneva, Switzerland: World Health Organization. 2015. [cited 2016 Aug 8] Available from: http://www.euro.who.int/__data/assets/pdf_file/0008/306179/Access-new-medicines-TR-PIO-collaboration-research.pdf?ua=1.
- Carone G, Schwierz C, Xavier A. Cost-containment policies in public pharmaceutical spending in the EU. Economic Papers 461, JEL classification: I11, I18. Social Science Electronic Publishing. 2012. [cited 2016 Sep 28] Available from SSRN: http://ssrn.com/abstract=2161803 or http://dx.doi.org/10.2139/ssrn.2161803.
- Howard DH, Bach PB, Berndt ER, Conti RM. Pricing in the market for anticancer drugs. The Journal of Economic Perspectives. 2015;29(1):139–162.
- Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013;121(22):4439–4442.
- Tefferi A, Kantarjian H, Rajkumar SV, et al. In support of a patient-driven initiative and petition to lower the high price of cancer drugs. Mayo Clin Proc. 2015;90(8):996–1000.
- Ghinea N, Kerridge I, Lipworth W. If we don’t talk about value, cancer drugs will become terminal for health systems. The Conversation. 2015. [cited 2016 Aug 17] Available from: https://ses.library.usyd.edu.au//bitstream/2123/13653/2/TheConv_if-we-dont-talk-about-value-2015.pdf.
- Brennan T, Shrank W. New expensive treatments for hepatitis C infection. Jama. 2014;312(6):593–594.
- Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis. 2011;6(1):1–8.
- Côté A, Keating B. What is wrong with orphan drug policies? Value Health. 2012;15(8):1185–1191.
- Simoens S, Picavet E, Dooms M, et al. Cost-effectiveness assessment of orphan drugs: a scientific and political conundrum. Appl Health Econ Health Policy. 2013;11(1):1–3.
- Cohen JP, Felix A. Are payers treating orphan drugs differently? Journal of market access & health policy. 2014;2. doi: 10.3402/jmahp.v2.23513.
- Barlas S. Are specialty drug prices destroying insurers and hurting consumers?: a number of efforts are under way to reduce price pressure. Pharm Ther. 2014;39(8):563.
- Lotvin AM, Shrank WH, Singh SC, et al. Specialty medications: traditional and novel tools can address rising spending on these costly drugs. Health Affairs. 2014;33(10):1736–1744.
- Phelan M, Cook C. A treatment revolution for those who can afford it? Hepatitis C treatment: new medications, profits and patients. BMC Infect Dis. 2014;14(Suppl 6):S5.
- Kaló Z, Annemans L, Garrison LP. Differential pricing of new pharmaceuticals in lower income European countries. Expert Rev Pharmacoecon Outcomes Res. 2013;13(6):735–741.
- Vogler S, Zimmermann N, Ferrario A, et al. Pharmaceutical pricing and reimbursement policies: challenges beyond the financial crisis. J Pharm Policy Pract. 2015;8(Suppl. 1):E1.
- Wilking N, Jönsson B. A pan-European comparison regarding patient access to cancer drugs. Stockholm: Karolinska Institutet in collaboration with Stockholm School of Economics; 2005.
- Wilking N, Kasteng F. A Review of Breast Cancer Care and Outcomes in 18 Countries in Europe, Asia, and Latin America. 2009. [cited 2016 Aug 17] Available from: http://www.comparatorreports.se/A_review_of_breast_cancer_care_and_outcomes_26Oct2009.pdf.
- Hoebert JM, Mantel-Teeuwisse AK, Van Dijk L, et al. Do rheumatoid arthritis patients have equal access to treatment with new medicines? Tumour necrosis factor-alpha inhibitors use in four European countries. Health Policy. 2012;104(1):76–83.
- Putrik P, Ramiro S, Kvien TK, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014;73(1):198–206.
- NHS England. High cost drugs [2016 May 7]. Available from: https://www.england.nhs.uk/resources/pay-syst/drugs-and-devices/high-cost-drugs/.
- Vogler S, Martikainen JE. Pharmaceutical pricing in Europe. In: Babar Z-U-D, editor. Pharmaceutical prices in the 21st century. Springer International Publishing; 2015. p. 343–370.
- Timur A, Picone G. Pharmaceutical price differences in the EU: investigation from cardiovascular disease drugs. Expert Rev Pharmacoecon Outcomes Res. 2009;9(3):251–256.
- Bouvy J, Vogler S. Background paper 8.3 pricing and reimbursement policies: impacts on innovation. In: World Health Organization, editor. Priority medicines for Europe and the world 2013 update. Geneva; 2013. [cited 2016 Aug 17] Available from: http://www.who.int/medicines/areas/priority_medicines/MasterDocJune28_FINAL_Web.pdf.
- Brekke KR, Holmås TH, Straume OR Are pharmaceuticals still inexpensive in Norway? a comparison of prescription drug prices in ten European countries. SNF Report No. 08/10. 2010.
- Vogler S, Kilpatrick K, Babar Z-U-D. Analysis of medicine prices in New Zealand and 16 European countries. Value Health. 2015;18(4):484–492.
- Petrou P, Talias MA. Navigating through the maze of pricing and affordability of branded pharmaceuticals in the midst of the financial crisis: a comparative study among five European recession countries, from a Cyprus perspective. J Pharm Ploicy Practice. 2016;9(1):1. .
- Kanavos P, Vandoros S, Irwin R, et al. Differences in costs of and access to pharmaceutical products in the EU. Brussels: European Parliament; 2011.
- Leopold C, Mantel-Teeuwisse AK, Seyfang L, et al. Impact of external price referencing on medicine prices–a price comparison among 14 European countries. Southern Med Review. 2012;5(2):34–41.
- Leopold C, Mantel-Teeuwisse AK, Vogler S, et al. Is Europe still heading to a common price level for on-patent medicines? an exploratory study among 15 Western European countries. Health Policy. 2013;112:209–216.
- Danzon PM, Furukawa MF. International prices and availability of pharmaceuticals in 2005. Health Affairs. 2008;27(1):221–233.
- Martikainen J, Kivi I, Linnosmaa I. European prices of newly launched reimbursable pharmaceuticals – a pilot study. Health Policy. 2005;74(3):235–246.
- The World Bank Group. World Bank Country and Lending Groups. 2015. [cited 2016 Sep 28] Available from the World Bank website:https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups.
- Gesundheit Österreich GmbH. Pharma price information (PPI) service. Vienna; 2014. [cited 2014 Nov 15]. Available from: http://www.goeg.at/en/PPI.
- Austrian Federal Ministry of Health. Regelung für die vorgehensweise der preiskommission bei der ermittlung des EU-Durchschnittspreises gemäß § 351c Abs. 6 ASVG [Regulation on Procedural Rules for Calculation of the EU average price according to Art. 351c.6 ASVG]. 2008. Accessible from: http://www.bmg.gv.at/home/Schwerpunkte/Medizin/Arzneimittel/Arzneimittelpreise/EU_Durchschnittspreise_laut_ASVG.
- Leopold C, Vogler S, Mantel-Teeuwisse AK, et al. Differences in external price referencing in Europe-A descriptive overview. Health Policy. 2012;104(1):50–60.
- Europe Economics. External price referencing. London; 2013. [cited 2016 Aug 17] Available from: http://www.europe-economics.com/publications/external_reference_pricing_-_final_report.pdf.
- Danzon PM, Furukawa MF. Prices and availability of pharmaceuticals: evidence from nine countries. Health affairs. 2003;Oct:W3-521 [cited 2016 Aug 17] Available from: http://content.healthaffairs.org/content/early/2003/10/29/hlthaff.w3.521.long.
- Danzon PM, Kim JD. International price comparisons for pharmaceuticals. Pharmacoeconomics. 1998;14(1):115–128.
- OECD. Pharmaceutical pricing policies in a global market. Paris: OECD; 2008.
- Kanavos PG, Vandoros S. Determinants of branded prescription medicine prices in OECD countries. Health Econ Policy Law. 2011;6(3):1–31.
- Vogler S, Zimmermann N, Leopold C, et al. Pharmaceutical policies in European countries in response to the global financial crisis. Southern Med Review. 2011;4(2):32.
- Leopold C, Mantel-Teeuwisse AK, Vogler S, et al. Effect of the economic recession on pharmaceutical policy and medicine sales in eight European countries. Bull World Health Organ. 2014;92(9):630–640.
- Belloni A, Morgan D, Paris V. (2016). “Pharmaceutical Expenditure And Policies: Past Trends And Future Challenges”, OECD Health Working Papers, No. 87, OECD Publishing, Paris. doi:10.1787/5jm0q1f4cdq7-en.
- Windmeijer F, De Laat E, Douven R, et al. Pharmaceutical promotion and GP prescription behaviour. Health Econ. 2006;15(1):5–18.
- Merkur S, Mossialos E. A pricing policy towards the sourcing of cheaper drugs in Cyprus. Health Policy. 2007;81(2–3):368–375.
- Brekke KR, Dalen DM, Strøm S. Should pharmaceutical costs be curbed?. 2012. [cited 2016 Aug 17] Available from: https://brage.bibsys.no/xmlui/bitstream/handle/11250/93886/Dalen_NEPR_2012.pdf?sequence=1.
- Håkonsen H, Horn AM, Toverud E-L. Price control as a strategy for pharmaceutical cost containment—what has been achieved in Norway in the period 1994–2004? Health Policy (Amsterdam, Netherlands). 2009;90(2–3):277–285.
- Vogler S, Lepuschütz L, Schneider P, et al. Study on enhanced cross-country coordination in the area of pharmaceutical product pricing. Vienna: Gesundheit Österreich Forschungs- und Planungs GmbH; 2016.
- Kanavos P, Nicod E, Espin J, Van Den Aardweg S. Short-and long-term effects of value-based pricing vs. external price referencing. EMiNet; 2010. [cited 2016 Aug 17] Available from: http://whocc.goeg.at/Literaturliste/Dokumente/FurtherReading/Short-%20and%20long-term%20effect%20of%20value-based%20pricing.pdf.
- Danzon PM, Towse A. Differential pricing for pharmaceuticals: reconciling access, R&D and patents. Int J Health Care Finance Econ. 2003;3(3):183–205.
- Danzon PM, Wang YR, Wang L. The impact of price regulation on the launch delay of new drugs—evidence from twenty‐five major markets in the 1990s. Health Econ. 2005;14(3):269–292.
- Godman B, Persson M, Miranda J, et al. changes in the utilization of venlafaxine after the introduction of generics in Sweden. Appl Health Econ Health Policy. 2013;11(4):383–393.
- Vogler S, Zimmermann N, De Joncheere K. Policy interventions related to medicines in European countries during 2010–2015: austerity measures or optimization of the pharmaceutical system? [In press 2016].
- Schwabe U, Paffrath D. Arzneiverordnungs-report 2013: aktuelle daten, kosten, trends und kommentare (drug prescription report 2013: current data, cost, trends and comments). Berlin, Heidelberg: Springer-Verlag; 2013.
- Health and Social Care Information Centre (HSCIC). Hospital prescribing. England 2012; 2013. [cited 2016 Aug 2016] Available from: http://digital.nhs.uk/catalogue/PUB12651/hosp-pres-eng-2012-rep.pdf.
- INFARMED. Estatística do medicamento 2012. 2014. [cited 2016 Aug 17] Available from: http://www.infarmed.pt/portal/page/portal/INFARMED/MONITORIZACAO_DO_MERCADO/OBSERVATORIO/ESTATISTICA_DO_MEDICAMENTO/ESTATISTICA_DO_MEDICAMENTO_ANTERIORES/EstMed-2012.pdf.
- IMS Health. Top 20 global products 2012 [15 May 2016]. Available from: https://www.imshealth.com/files/web/Corporate/News/Top-Line Market Data/2012/Top_20_Global_Products_2012_2.pdf.
- Godman B, Malmström RE, Diogene E, et al. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? Expert Rev Clin Pharmacol. 2015;8(1):77–94.
- De Weerdt E, Simoens S, Hombroeckx L, et al. Causes of drug shortages in the legal pharmaceutical framework. Regul Toxicol Pharmacol. 2015;71:251–258.
- Gray A, Manasse HR Jr. Shortages of medicines: a complex global challenge. Bull World Health Organ. 2012;90(3):158.
- Ferrario A, Kanavos P. Managed entry agreements for pharmaceuticals: the European experience. EMINet, London School of Economics and Political Science. 2013 Apr;154. [cited 2016 Aug 17] Availavle at: http://eprints.lse.ac.uk/50513/1/__Libfile_repository_Content_Ferrario,%20A_Ferrario_Managed_%20entry_%20agreements_2013_Ferrario_Managed_%20entry_%20agreements_2013.pdf.